Alignment Healthcare stock
ALHCNASDAQAlignment Healthcare, Inc., HealthcareISIN US01625V1044
41Score 41 out of 100, Weak
Price and trend
39 / 100
Price history
−55% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 53% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 43).
The price is 69% below its 52-week high. Largest decline in 6 years: 84% (June 2021 to April 2024).
Chart figures for advanced users
- SMA 50$8.79
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.12
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)43
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.00
- The lowest closing price of the last twelve months.
- Resistance$24.56
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alignment Healthcare, Inc. belongs to the Medical (Healthcare Plans) industry (United States) and, with a market value of $1.57B, is number 12 of 12 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.95B (up 46.1% year on year) and a loss of $724K.
- For fiscal 2026, analysts expect on average revenue of $5.26B (up 33.2%) and adjusted earnings per share of −$0.03.
Show more
- MEQIRI Score 41 out of 100 (Weak): rank 530 of 714 in Healthcare, median 53.
- Our model puts fair value at $16.34, with the price 53% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 32.7% a year since 2020, Medical (Healthcare Plans) median 11.9%.Growth 70
- Earnings turn into cashFree cash flow 288% of earnings over the last 12 months.
- More cash than debtCash $742.95M, financial debt $330.7M.
Weaknesses
- Interest barely coveredOperating profit covers interest only 0.9 times.Stability 39
- Share price fell sharplyDown 54% over the last 12 months.Momentum 17
- Volatile share priceVolatility 71% a year over the last 12 months.Stability 39
Its standout strength is growth, while fundamentals and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- high price swings
- weak fundamentals
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $10.89 and expensive above $32.68 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $29.49 (cash-flow model) and $3.19 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $14.02, at 7.8% it would be $19.80.
Possible value trap: looks cheap, but score below 50, high risk, weak balance sheet.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (23).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 35.9% on the twelve months before. Revenue has grown strongly since 2019, at around 32% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 12%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 29 Oct 2026EPS reported −$0.04 (expected −$0.04)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 121.8% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.03−121.8%
- Revenue
- $5.26B+0.9%
- Earnings per share
- $0.16−52.1%
- Revenue
- $6.57B+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −18.8%2026 revenue guidance raised to about $5.2 billion at the midpoint (up 32%), low end of adjusted gross profit raised by $10 million and low end of adjusted EBITDA by $7 million.
“We are raising the low end of our adjusted gross profit range by $10 million and increasing the low end of our adjusted EBITDA guidance range by $7 million to reflect increased confidence in our full year objectives following a strong first half of the year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $197,627 in total. 4 insiders sold, $33.42M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Kim HyongSale
6 Oct 2026, Chief Medical Officer
- Shares
- 32,479
- Price
- $8.30
- Value
- $269,576
- Konowiecki Joseph SSale
17 Sept 2026, EVP, Corporate Affairs
- Shares
- 23,511
- Price
- $8.61
- Value
- $202,430
- Kao John ESale
14 Sept 2026, Chief Executive Officer
- Shares
- 27,400
- Price
- $13.00
- Value
- $356,200
Show 16 more
- Maroney Dawn ChristineSale
11 Sept 2026, President
- Shares
- 122,707
- Price
- $12.68
- Value
- $1.56M
- Kao John ESale
11 Sept 2026, Chief Executive Officer
- Shares
- 385,270
- Price
- $12.68
- Value
- $4.89M
- Kao John ESale
10 Sept 2026, Chief Executive Officer
- Shares
- 172,600
- Price
- $12.96
- Value
- $2.24M
- Maroney Dawn ChristineSale
14 Aug 2026, President
- Shares
- 5,000
- Price
- $14.00
- Value
- $70,000
- Kao John ESale
10 Aug 2026, Chief Executive Officer
- Shares
- 298,000
- Price
- $13.88
- Value
- $4.14M
- Maroney Dawn ChristineSale
15 Jul 2026, President
- Shares
- 177,068
- Price
- $20.83
- Value
- $3.69M
- Kao John ESale
10 Jul 2026, Chief Executive Officer
- Shares
- 298,000
- Price
- $19.86
- Value
- $5.92M
- Konowiecki Joseph SSale
1 Jul 2026, EVP, Corporate Affairs
- Shares
- 25,000
- Price
- $24.00
- Value
- $600,000
- Konowiecki Joseph SSale
26 Jun 2026, EVP, Corporate Affairs
- Shares
- 25,000
- Price
- $23.00
- Value
- $575,000
- Konowiecki Joseph SSale
18 Jun 2026, EVP, Corporate Affairs
- Shares
- 25,000
- Price
- $22.00
- Value
- $550,000
- Maroney Dawn ChristineSale
15 Jun 2026, President
- Shares
- 30,000
- Price
- $19.55
- Value
- $586,425
- Kim HyongSale
12 Jun 2026, Chief Medical Officer
- Shares
- 35,951
- Price
- $19.86
- Value
- $713,947
- Konowiecki Joseph SSale
11 Jun 2026, EVP, Corporate Affairs
- Shares
- 25,000
- Price
- $21.00
- Value
- $525,000
- Kao John ESale
10 Jun 2026, Chief Executive Officer
- Shares
- 298,000
- Price
- $20.36
- Value
- $6.07M
- Kent Mark D.Purchase
2 Jun 2026, President - MSO
- Shares
- 14,848
- Price
- $13.31
- Value
- $197,627
- Maroney Dawn ChristineSale
15 May 2026, President
- Shares
- 30,000
- Price
- $16.09
- Value
- $482,565
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Alignment Healthcare
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Plans)
The next larger companies by market value
- CignaCI $79.43B66
- HumanaHUM $53.6B63
- CenteneCNC $34.89B54
- Molina HealthcareMOH $10.92B50
- Oscar HealthOSCR $9.93B71
- BradsaudeSAUD3.SA $8.69B80
- ProgynyPGNY $2.69B79
- Clover Health InvestmentsCLOV $2.64B52
ETFs that hold Alignment Healthcare
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.12% | 0.40% | €807M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.12% | 0.30% | €185.82M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.09% | 0.30% | €2.28B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.